Bavarian Nordic updates phase III booster study plans, sets launch for August

The biotech firm aims to compare its Covid-19 vaccine candidate, ABNCoV2, with Pfizer/Biontech’s Comirnaty in a controlled, double-blind trial.
Photo: Sven Hoppe/AP/Ritzau Scanpix
Photo: Sven Hoppe/AP/Ritzau Scanpix
by christian bundgaard, translated by daniel pedersen

Bavarian Nordic has scheduled its phase III trial of its booster candidate against Covid-19, dubbed ABNCoV2, in August, according to a press release.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading